epclusa access- velpatasvir and sofosbuvir tablet, film coated
gilead sciences, inc. - velpatasvir (unii: kcu0c7rs7z) (velpatasvir - unii:kcu0c7rs7z), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - velpatasvir 100 mg - epclusa™ is indicated for the treatment of adults and pediatric patients 6 years of age and older or weighing at least 17 kg with chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 infection [see dosage and administration (2.2, 2.3, 2.4) and clinical studies (14)] : - without cirrhosis or with compensated cirrhosis - with decompensated cirrhosis for use in combination with ribavirin. epclusa and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2, 2.3, 2.4)]. risk summary if epclusa is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information
harvoni
gilead sciences (nz) - ledipasvir 90mg; ; ; sofosbuvir 400mg; ; ; - film coated tablet - 90mg/400mg - active: ledipasvir 90mg sofosbuvir 400mg excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry orange 85f13912 - harvoni is indicated for the treatment of chronic hepatitis c (chc) infection in adults and in pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5 or 6 without cirrhosis or with compensated cirrhosis.
epclusa- velpatasvir and sofosbuvir tablet, film coated epclusa- velpatasvir and sofosbuvir pellet
gilead sciences, inc. - velpatasvir (unii: kcu0c7rs7z) (velpatasvir - unii:kcu0c7rs7z), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - velpatasvir 100 mg - epclusa is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 infection [see dosage and administration (2.2, 2.3, 2.4) and clinical studies (14)] : - without cirrhosis or with compensated cirrhosis - with decompensated cirrhosis for use in combination with ribavirin. epclusa and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2, 2.3, 2.4)]. risk summary if epclusa is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information for more information on ribavirin-associated risks of use during pregnancy. no adequate human data are available to establish whether or not epclusa poses a risk to pregnancy outcomes. in
harvoni 90mg400mg tablets
gilead sciences international ltd - ledipasvir; sofosbuvir - tablet - 90mg ; 400mg
harvoni- ledipasvir and sofosbuvir tablet, film coated harvoni- ledipasvir and sofosbuvir tablet, film coated harvoni- ledipas
gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - harvoni is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis c virus (hcv) [see dosage and administration (2.2 and 2.3) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and administration (2.2)] . risk summary if harvoni is administered with ribavirin, the combination regimen is contraindicated in pregnant women and in men whose female partners are pregnant. refer to the ribavirin prescribing information for more information on ribav
harvoni access- ledipasvir and sofosbuvir tablet, film coated
gilead sciences, inc - ledipasvir (unii: 013te6e4wv) (ledipasvir - unii:013te6e4wv), sofosbuvir (unii: wj6ca3zu8b) (sofosbuvir - unii:wj6ca3zu8b) - ledipasvir 90 mg - adult patients : harvoni is indicated for the treatment of adult patients with chronic hepatitis c virus (hcv) [see dosage and administration (2.2) and clinical studies (14)] : - genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis - genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin - genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin pediatric patients : harvoni is indicated for the treatment of pediatric patients 12 years of age and older or weighing at least 35 kg with hcv genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis [see dosage and administration (2.3) and clinical studies (14.6)] . if harvoni is administered with ribavirin, the contraindications to ribavirin also apply to this combination regimen. refer to the ribavirin prescribing information for a list of contraindications for ribavirin [see dosage and ad
vosevi 400mg100mg100mg tablets
gilead sciences international ltd - voxilaprevir; velpatasvir; sofosbuvir - tablet - 100mg ; 100mg ; 400mg
sofgen
hetero labs limited - sofosbuvir - tablet - each tablet contains sofosbuvir 400mg
myhep dvir film coated tablet daclatasvir dihydrochloride equivalent to daclatasvir 60 mg and sofosbuvir 400 mg
mylan laboratories limited, india - daclatasvir dihydrochloride - film coated tablet - daclatasvir dihydrochloride equivalent to daclatasvir 60 mg and sofosbuvir 400 mg
ofost® 10 iu/ml
10 glass ampoules (1ml) -